{"name":"Otologic Pharmaceutics, Inc.","slug":"otologic-pharmaceutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"HPN-07","genericName":"HPN-07","slug":"hpn-07","indication":"Other","status":"phase_1"},{"name":"NAC","genericName":"NAC","slug":"nac","indication":"Ototoxicity prevention in patients receiving ototoxic medications (e.g., aminoglycosides, cisplatin)","status":"marketed"}]}],"pipeline":[{"name":"HPN-07","genericName":"HPN-07","slug":"hpn-07","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NAC","genericName":"NAC","slug":"nac","phase":"marketed","mechanism":"NAC (N-acetylcysteine) is a mucolytic and antioxidant agent that breaks down mucus viscosity and replenishes intracellular glutathione to reduce oxidative stress.","indications":["Ototoxicity prevention in patients receiving ototoxic medications (e.g., aminoglycosides, cisplatin)","Chronic bronchitis and mucolytic therapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQSzg1LUhmejlya1UyNHlEWDhzNndOWW9aS3Mwa1ozQmw1RkVEMGxPV056bmJXRUNkRzNGSmI1cTlMQTB0dmgxSElEWTJpYlJ5WGs2RXg5dEhuMzU3LVBUVmQwYVBTS3hPNlF6R2sxLVljeHY5SU9tRWRaME11SGlISjZENkNSMGpMR1hZc1hqaUNpSEpKeUx3VmdIZ1ZmWUtWcmk4TE9hbUpnMWhYQ1VybTMwcDU5LWVmNjZGdTF4dm50eFBHSk85TjEzc3hoVUpwdTlXazdacjlfN21tTmFEMGt2eWJ1YnJvNHVvN1ZB?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Hearing Loss Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight - Barchart.com","headline":"Hearing Loss Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxQamM4TFphdFVZcU5vWEg3MktnSkQyMUhLMGV5bHdodlQtdlRKUXhyTjdwbUcwRU1abUt5QlhVaG9lSWV3cXRoanNoUDZpUTRCajBHdnpUdkZKUUlESnZzbFNMeFpyRmRzX1JhZ2JfczhlbUtOd01hV3NjQ1lzeDQ5QlFmQlFLU1lvQ2ZYZ2owRnMtT2Z2dEpRbDAzcS1ueXpzSVp4YjBMazNmOGZ3TXJTWTdaOUVVNVJrMzJhanBoLWg4eUdqckt0dFpfSzJUYTFCaEdsT01UcUVVQjZleFFpWmZQb2w4eFlObDVOd3pfS1pUa05yUTlzRUEtOVI0TkZPeWNTdVhBaDJ6cEpkZF9MYzExR0htd0NCNmhlalZRSmNkU245ZXg5N2h6QkhWNTdpUEJZ?oc=5","date":"2026-02-25","type":"pipeline","source":"PR Newswire","summary":"Tinnitus Treatment Landscape Set for Significant Market Upswing During Forecast Period (2026-2036) as Need for Effective Therapies Intensifies | DelveInsight - PR Newswire","headline":"Tinnitus Treatment Landscape Set for Significant Market Upswing During Forecast Period (2026-2036) as Need for Effective","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQUDZ6dFZ2eW5wVzBNRXctS1lsNnBCU2Z4Q2YxRDdWaU5JVXR2MU5xTDFyZUIwX1ViWUl0d0V6MkQtekhlRFkzM2lmYXpHR09Fd1MwSEVmdUlPU0FhYnpyVjVaT3VrbVN5aWs3N2EwRDBmb19xOUhES1QyS29Ec09BbVlwVGFzZ3BiV1FQTnktXzJhT25CWHNBeGtvR3NxMXZnbDM3MllwS0NNQVFkcUNrX0VEOGhMWTFQMi0zaUVKbjA5dTRYMmNiOVFTLUUtb0YwSjg4REQ0TWJEcVkwQTltdGtBMUU3NkpOeUMzMWhYVWxyNUFBRXg3WXFIZm1NNnBodTdXQW94bFN6NlVfNTZtUVhQUFVjSVBGVVNzSWRRaXFCcFBlaXhLUg?oc=5","date":"2024-10-30","type":"trial","source":"globenewswire.com","summary":"Advancements in Sensorineural Hearing Loss Clinical Trial - globenewswire.com","headline":"Advancements in Sensorineural Hearing Loss Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE9mWWV0OFVUZElBRkZfc1lEWWZlcnd5S2I3V2tRSGFTOEt4REhFMTlwVUxCUk0wTzQxaVB2cTdPWmF2ZmRST2dzNHJJYTl5Z3l4WmhVal9kZGVZbnB6VmxPRmgyaw?oc=5","date":"2020-02-12","type":"deal","source":"The Hearing Review","summary":"Oblato Acquires Rights to Hearing Loss Drug - The Hearing Review","headline":"Oblato Acquires Rights to Hearing Loss Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOSDdsckkxVDE2OXZzVUFDTFpjRzNyQ29UZkg2RHJVQUZhM0otWVhKa1BiTWlZdVB0Zjh3YXBmMV9ubUJkckoySEdiT2U0WGNMaUh4dGZBczk1N3Vrd19LWXZfY21Ldk4yUEtKb2ZoMWlOX2FkNkFmdjFaZF9nNTZPQno5Qy1IT1lTOHVXdGhnaVh5cm5yT1RpS0MyNFZBTDhWSDlJTFBoOW9PVWNXRVFNLTYxVTNSRFNpTVpDRVpXS1Y2RkZTVEEzYg?oc=5","date":"2020-02-11","type":"deal","source":"OKC VeloCity","summary":"Biotech company acquires hearing loss drug discovered by Hough Ear Institute scientists - OKC VeloCity","headline":"Biotech company acquires hearing loss drug discovered by Hough Ear Institute scientists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOZDNEMVMzSml3SHNMZEZITGVtY2xPY0JQQkJaNV9LVDhOdmJ1LTNtN0MxcEMwTGRiRDJEdHdnWVZHemhwWWU0dTRzMFdHVmZuZzFnQWt6ZkozMGNHQ2VKRDg2Tlh3WkFfTVVMd1RZcTltd2hVMnRnVTd3TVVlZEo2c0wtUWtnV3UwQ0VR?oc=5","date":"2017-04-13","type":"deal","source":"The Journal Record","summary":"OU scientist strikes deal with major investor - The Journal Record","headline":"OU scientist strikes deal with major investor","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}